Drug General Information (ID: DDII5VBS3F)
Drug Name			Measles virus vaccine live attenuated		Drug Info		Ozanimod		Drug Info
Drug Type		Vaccine				Small molecule
Therapeutic Class		Vaccine				Selective Immunosuppressants

Mechanism of Measles virus vaccine live attenuated-Ozanimod Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Measles virus vaccine live attenuated				Ozanimod
Mechanism		Vaccine or toxoid				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Measles virus vaccine live attenuated when combined with Ozanimod

Recommended Action
Management		The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment. If live attenuated vaccine immunizations are required, administration should occur at least 1 month prior to initiation of ozanimod. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ozanimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ozanimod. In patients who have recently been vaccinated, ozanimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur.

References
1	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.